| Nome del prodotto |
D-chiro-Inositol, 1,5,6-trideoxy-3-O-beta-D-glucopyranosyl- |
| Nome inglese |
D-chiro-Inositol, 1,5,6-trideoxy-3-O-beta-D-glucopyranosyl-; Validamycin A; Validamycin; (1S-(1a,4a,5B,6a))-1,5,6-Trideoxy-3-O-B-D-glucopyranosyl-5-
(hydroxymethyl)-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2-
cyclohexen-1-yl)amino)-d-chiro-inositol; (1S-(1alpha,4alpha,5beta,6alpha))-1,5,6-trideoxy-4-O-beta-D-
glucopyranosyl-5-(hydroxymethyl)-1-((4,5,6-trihydroxy-3-
(hydroxymethyl)-2-cyclohexen-1-yl)amino)-D-chiro-inositol; 1L-(1,3,4/2,6)-2,3-Dihydroxy-6-hydromethyl-4-((1S,4R,5S,6S)-
4,5,6-trihydroxy-3-hydroxymethylcyclohex-2-
enylamino)cyclohexyl beta-D-glucopyranoside; 1L-(1,3,4/2,6)-2,3-Dihydroxy-6-hydroxymethyl-4-
((1S,4R,5S,6S)-4,5,6-trihydroxy-3-hydroxymethylcyclohex-2-
enylamino)cyclohexyl beta-D-glucopyranoside; D-1,5,6-Trideoxy-3-O-beta-D-glucopyranosyl-5-
(hydroxymethyl)-1-((4,5,6-trihydroxy-3-(hydroxymethyl)-2-
cyclohexen-1-yl)amino)-D-chiroinositol;
; (1S,2S,3R,4R,6S)-2,3-dihydroxy-6-(hydroxymethyl)-4-{[(4S,5R,6R)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}cyclohexyl beta-D-glucopyranoside; (1R,2R,3S,4S,6R)-2,3-dihydroxy-6-(hydroxymethyl)-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}cyclohexyl beta-D-glucopyranoside; 2,3-dihydroxy-6-(hydroxymethyl)-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}cyclohexyl hexopyranoside |
| Formula molecolare |
C20H35NO13 |
| Peso Molecolare |
497.4908 |
| InChI |
InChI=1/C20H35NO13/c22-3-6-1-8(12(26)15(29)11(6)25)21-9-2-7(4-23)19(17(31)13(9)27)34-20-18(32)16(30)14(28)10(5-24)33-20/h1,7-32H,2-5H2 |
| Numero CAS |
37248-47-8 |
| Struttura molecolare |
|
| Densità |
1.698g/cm3 |
| Punto di fusione |
130-135℃ |
| Punto di ebollizione |
813.658°C at 760 mmHg |
| Indice di rifrazione |
1.689 |
| Punto d'infiammabilità |
445.885°C |
| Pressione di vapore |
0mmHg at 25°C |
| Simboli di pericolo |
|
| Codici di Rischio |
|
| Sicurezza Descrizione |
|
|
IT
CN
CZ
DE
EN
ES
FR
GR
HU
ID
IL
IN
IR
JP
KR
MY
NL
NO
PL
PT
RU
SA
TR
